Large neutral amino acid transporter enables brain drug delivery via prodrugs

被引：121

作者：

Gynther, Mikko ^{[1
]}

Laine, Krista ^{[1
]}

Ropponen, Jarmo ^{[1
]}

Leppanen, Jukka ^{[1
]}

Mannila, Anne ^{[1
]}

Nevalainen, Tapio ^{[1
]}

Savolainen, Jouko ^{[2
]}

Jarvinen, Ton-Ti ^{[1
]}

Rautio, Jarkko ^{[1
]}

机构：

[1] Univ Kuopio, Dept Pharmaceut Chem, FI-70211 Kuopio, Finland

[2] Fennopharma Ltd, FI-70210 Kuopio, Finland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2008年 / 51卷 / 04期

关键词：

ENDOTHELIAL-CELLS; L-DOPA; BARRIER; DESIGN; LINE; LAT1;

D O I：

10.1021/jm701175d

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The blood-brain barrier efficiently controls the entry of drug molecules into the brain. We describe a feasible means to achieve carrier-mediated drug transport into the rat brain via the specific, large neutral amino acid transporter (LAT1) by conjugating a model compound to L-tyrosine. A hydrophilic drug, ketoprofen, that is not a substrate for LAT1 was chosen as a model compound. The mechanism and the kinetics of the brain uptake of the prodrug were determined with an in situ rat brain perfusion technique. The brain uptake of the prodrug was found to be concentration-dependent. In addition, a specific LAT1 inhibitor significantly decreased the brain uptake of the prodrug. Therefore, our results reveal for the first time that a drug-substrate conjugate is able to transport drugs into the brain via LAT1.

引用

页码：932 / 936

页数：5

共 32 条

[1] Prodrugs for improved CNS delivery [J].

Anderson, BD .

ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) :171-202

[2] Carrier mediated uptake of L-tyrosine and its competitive inhibition by model tyrosine linked compounds in a rabbit corneal cell line (SIRC) - strategy for the design of transporter/receptor targeted prodrugs [J].

Balakrishnan, A ;

Jain-Vakkalagadda, B ;

Yang, C ;

Pal, D ;

Mitra, AK .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 247 (1-2) :115-125

[3] Selective expression of the large neutral amino acid transporter at the blood-brain barrier [J].

Boado, RJ ;

Li, JY ;

Nagaya, M ;

Zhang, C ;

Pardridge, WM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) :12079-12084

[4] Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems [J].

Bodor, N ;

Buchwald, P .

ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :229-254

[5] The multidrug resistance protein family [J].

Borst, P ;

Evers, R ;

Kool, M ;

Wijnholds, J .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1461 (02) :347-357

[6] MULTIDRUG-RESISTANCE GENE (P-GLYCOPROTEIN) IS EXPRESSED BY ENDOTHELIAL-CELLS AT BLOOD-BRAIN BARRIER SITES [J].

CORDONCARDO, C ;

OBRIEN, JP ;

CASALS, D ;

RITTMANGRAUER, L ;

BIEDLER, JL ;

MELAMED, MR ;

BERTINO, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (02) :695-698

[7] XP13512 [(±)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug:: II.: Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys [J].

Cundy, KC ;

Annamalai, T ;

Bu, L ;

De Vera, J ;

Estrela, J ;

Luo, W ;

Shirsat, P ;

Torneros, A ;

Yao, FM ;

Zou, J ;

Barrett, RW ;

Gallop, MA .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :324-333

[8] Expression of large amino acid transporter LAT1 in rat brain endothelium [J].

Duelli, R ;

Enerson, BE ;

Gerhart, DZ ;

Drewes, LR .

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2000, 20 (11) :1557-1562

[9] Experimental methods for studying drug uptake in the head and brain [J].

Foster, KA ;

Roberts, MS .

CURRENT DRUG METABOLISM, 2000, 1 (04) :333-356

[10]

GOLDENBERG GJ, 1979, J BIOL CHEM, V254, P1057

← 1 2 3 4 →